GARFIELD-AF Registry

GARFIELD-AF registry

GARFIELD-AF is the largest ongoing prospective registry of patients with newly diagnosed atrial fibrillation

Back to GARFIELD-AF
Keep Up to Date Login
Menu
  • Home
  • About
    • About GARFIELD-AF
    • Our Governance
    • About Atrial Fibrillation
    • External Links
    • Close
  • Key Findings

      • For a summary of our published findings, explore the GARFIELD tree either by clicking on the branches or by using the navigation links below.

        • Burden of Disease
        • Risk Stratification
        • Treatment Practices
        • Therapy Persistence
        • Clinical Outcomes
        • Geographic Differences
        • Health Economics
    Close
  • Publications & Presentations
  • News & Events
    • GARFIELD in Focus
    • Close
  • Media
  • Community Page

American College of Cardiology 66th Annual Meeting (ACC.17)

Previous Page

GARFIELD-AF insights on early mortality, AC treatment in low stroke-risk patients and decline of AP monotherapy, shared at ACC.17

The world’s leading cardiovascular professionals came together in Washington, DC in March for three full days of innovative education, ground-breaking science and interactive debates and discussion.

Professors Samuel Goldhaber, John Camm and Freek Verheugt, members of our Steering Committee, all spoke at ACC.17 to share GARFIELD-AF insights. Below are some highlight quotes from their presentations:

 

GARFIELD-AF registry speaks on early mortality in patients with newly diagnosed atrial fibrillation (AF)

“There is a clear need for clinicians to provide integrated cardiovascular management to help detect early warning signs of possible early mortality; this is because cardiovascular death and co-morbidities appear to be important components of the early mortality.” – Professor Samuel Goldhaber

 

Net clinical benefit of anticoagulant (AC) treatment uncertain in guideline-defined low stroke-risk patients

“For guideline-defined low risk stroke patients (i.e. women with a CHA2DS2-VASc score of 2, men with a CHA2DS2-VASc score of 1), risk of stroke was not clearly reduced by AC ± antiplatelet (AP), but was associated with a 3-4 times higher risk of major bleeds.” – Professor John Camm

 

AP scripts declining but still an important part of stroke prevention strategies in AF

“Antiplatelet monotherapy for stroke prevention is still prescribed in around 10 percent of AF patients eligible for anticoagulants, who do not have vascular disease.” – Professor Freek Verheugt

Previous Page

Community members, please login to view additional information

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up Ongoing
Study end: 2018

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

garfield@tri-london.ac.uk Contact Us

Follow Us

Keep up to date

Sign up to our newsletter to receive news and updates from us

Keep Up to Date

Funding

The GARFIELD-AF registry is funded by an unrestricted research grant from Bayer AG

© Copyright TRI 2019

All Rights Reserved. No part of this site may be reproduced without our permission.

  • About TRI
  • Cookie Notice
  • Privacy Policy
  • Terms of Use

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup






Please see our Privacy Policy and Cookie Policy

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

E: garfield@tri-london.ac.uk
T: 0203 198 9947

By continuing to browse the site you are agreeing to our use of cookies.